Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1/2. fázis

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases

A legfontosabb adatok

Ki végzi
Fudan University
Hol
Kína2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1/2. fázis
Résztvevők
139 fő, tervezett
Kezdés
2025. máj. 12.
Várható befejezés
2027. jún. 28.
A vizsgálat típusa
Beavatkozással járó, 10 csoport
A vizsgált kezelések
  • T-DXd
A regiszteradat frissítve
2026. október 26.

Ki vehet részt

The trial is looking for adults with HER2-expressing advanced or spread breast cancer that has reached the brain lining (leptomeningeal metastasis) and/or the brain. T-DXd is given into the spinal fluid together with treatment through the blood.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
Advanced or metastatic breast cancer with leptomeningeal metastasis. People with active brain metastases only need at least one brain tumour that can be measured on scans (RANO-BM criteria). Some groups need cancer in the brain or brain lining that is growing.
Korábbi kezelés
No radiotherapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy or surgery within 2 weeks before joining (or within 5 half-lives of the earlier therapy, whichever is shorter). Side effects of earlier treatment must have eased to Grade 1 or lower. Some groups are for people who already had T-DXd, others for people who never had it.
Biomarker vagy leletérték
HER2-expressing breast cancer: HER2-positive or HER2-low (IHC 1+ or 2+/ISH-), depending on the group.
A részvétel fő kizáró okai
  • Another cancer in the past 5 years, except some early or skin cancers that were treated and gone
  • Past lung inflammation (ILD/pneumonitis) needing steroids, or current or suspected ILD/pneumonitis
  • Known HIV infection, active hepatitis B or C, or uncontrolled infections needing IV medicines
  • Active autoimmune disease, or immunosuppressants or systemic steroids over 10 mg/day prednisone equivalent within 2 weeks
  • Pregnant or breastfeeding women, or people unwilling or unable to use effective birth control
A regiszter összes feltétele (18)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Age ≥18 years, regardless of gender
  • HER2-expressing advanced or metastatic breast cancer
  • Leptomeningeal metastasis
  • Subjects with active brain metastases only must have at least one intracranially measurable lesion (RANO-BM criteria)
  • Adequate organ and bone marrow function
  • No radiotherapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or surgery within 2 weeks prior to enrollment (or within 5 half-lives of prior therapy, whichever is shorter)
  • All prior treatment-related toxicities must have resolved to ≤Grade 1

Ki nem vehet részt

  • Uncontrolled concurrent illnesses including, but not limited to: persistent or active infections, uncontrolled or clinically significant cardiovascular diseases, severe chronic gastrointestinal disorders with diarrhea, or psychiatric/social conditions that may compromise compliance with study requirements, significantly increase AE risks, or impair the subject's ability to provide written informed consent
  • Use of immunosuppressants or systemic corticosteroids (>10 mg/day prednisone equivalent) for immunosuppression within 2 weeks prior to first dose (excluding intranasal/inhaled corticosteroids)
  • Diagnosis of other malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, other in situ carcinomas, or papillary thyroid carcinoma
  • History of (non-infectious) ILD/non-infectious pneumonitis requiring steroid therapy, current ILD/non-infectious pneumonitis, or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging during screening
  • Any active autoimmune disease or history of autoimmune disease with potential recurrence
  • Uncontrolled infections requiring IV antibiotics, antivirals, or antifungals
  • Active primary immunodeficiency, known HIV infection, active HBV (HBsAg+ with HBV DNA ≥500 IU/mL) or HCV infection. HCV antibody-positive subjects are eligible only if PCR confirms HCV RNA negativity
  • Radiographic evidence of tumor encasement/invasion of major blood vessels, or investigator-determined high risk of fatal hemorrhage due to probable vascular invasion during treatment
  • Any other condition deemed by investigators to potentially affect trial conduct or outcome interpretation
  • Clinically significant pulmonary comorbidities
  • Pregnant/lactating women, or subjects of reproductive potential unwilling/unable to use effective contraception

Alkalmassági kérdőív

Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.

  • Életkor
  • Breast cancer

Ez a vizsgálat jelenleg itt érhető el: Kína.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Multiple trials confirm systemic T-DXd efficacy in HER2+ breast cancer with leptomeningeal/brain metastases, yet median LM survival remains 3-4 months, highlighting unmet needs. While systemic therapies improve survival, intracranial disease control remains limited due to poor BBB penetration. Preclinical data show no detectable T-DXd/DXd in CSF, though intrathecal trastuzumab demonstrates preliminary safety/efficacy in HER2+ LM.

A teljes eredeti leírásKevesebb

This study evaluates intrathecal/intra-Ommaya T-DXd plus systemic therapy in active HER2+ meningeal/brain metastases, assessing safety, intracranial efficacy, and CSF/peripheral blood T-DXd distribution to clarify BBB penetration potential. Findings may guide novel therapeutic strategies for this high-need population.

A vizsgálat 10 csoportja

  • Phase I/Arm A(Intrathecal Dose-Escalation Phase)A vizsgált kezelés

    Population : T-DXd-naïve subjects with leptomeningeal metastases (LM), with or without concurrent brain metastases (BM). Cycle 1 : Intrathecal (IT) T-DXd monotherapy to assess cerebrospinal fluid (CSF) and systemic pharmacokinetics (PK). Cycles 2+ : IT T-DXd combined with intravenous (IV) T-DXd in a dose-escalation design to determine the maximum tolerated dose (MTD) . DLT Evaluation : The first two cycles serve as the dose-limiting toxicity (DLT) observation window . Endpoint : The recommended Phase 2 dose (RP2D) will be determined by investigator assessment

    Kezelés: T-DXd

  • Phase I/Arm B(Systemic-to-Intrathecal Transition Phase)A vizsgált kezelés

    Population : T-DXd-naïve subjects with LM ± BM. Cycle 1 : IV T-DXd monotherapy to characterize CSF and systemic PK profiles. Cycles 2+ : IT administration of the RP2D of T-DXd combined with IV therapy

    Kezelés: T-DXd

  • Phase II/Arm AA vizsgált kezelés

    HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy

    Kezelés: T-DXd

  • Phase II/Arm BA vizsgált kezelés

    HER2-low (IHC 1+ or 2+/ISH-) advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy

    Kezelés: T-DXd

  • Phase II/Arm CA vizsgált kezelés

    HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy

    Kezelés: T-DXd

  • Phase II/Arm DA vizsgált kezelés

    HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy

    Kezelés: T-DXd

  • Phase II/Arm EA vizsgált kezelés

    T-DXd-naïve HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases

    Kezelés: T-DXd

  • Phase II/Arm FA vizsgált kezelés

    T-DXd-naïve HER2-low advanced breast cancer with progressive leptomeningeal and/or brain metastases

    Kezelés: T-DXd

  • Phase II/Arm GA vizsgált kezelés

    T-DXd-naïve HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)

    Kezelés: T-DXd

  • Phase II/Arm HA vizsgált kezelés

    T-DXd-naïve HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)

    Kezelés: T-DXd

Következő lépések

Az orvosodnak

Kérdőlap az orvosnak

PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 2 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.

A PDF letöltése

PDF, US Letter, 1–2 oldal. A4 méretben

A vizsgálati csapatnak

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluating Safety and Efficacy of INtrathecal or Ommaya ReserVoir Administration of T-DXd in Patients With HER2-Expressing Breast Cancer With Active Leptomeningeal and/or Brain Metastases Based on Systemic Therapy: Phase I/II Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Kérdések a feltételekről
Forrás: NCT07134153: ki vehet részt
A regiszteradat frissítve
2026. október 26.